Beranda › Mieloma Multipel › Nebraska › Lincoln
Uji klinis Mieloma Multipel di Lincoln, NE
3 studi untuk Mieloma Multipel mencari peserta di lokasi sekitar Lincoln (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Menerima pesertaFase 3
- NHO Revive Research Institute, LLC, Lincoln
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Menerima pesertaFase 3
- Bryan Medical Center, Lincoln
- NHO Revive Research Institute, LLC, Lincoln
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Menerima pesertaFase 1
- NHO Revive Research Institute, LLC /ID# 267869, Lincoln
Uji klinis Mieloma Multipel di kota lain
- New York City, NY60 studi
- Boston, MA42 studi
- Atlanta, GA41 studi
- Houston, TX38 studi
- Durham, NC37 studi
- Nashville, TN32 studi
- Denver, CO27 studi
- Rochester, MN24 studi
- St. Louis, MO24 studi
- Columbus, OH24 studi
- Baldwin Park, CA23 studi
- Chicago, IL22 studi
Studi lain di Lincoln
- Kanker Paru Non-Sel Kecil16 studi
- Gagal Jantung8 studi
- Kanker Paru7 studi
- Penyakit Arteri Koroner5 studi
- Kanker Payudara4 studi
- Obesitas4 studi
- Skizofrenia4 studi
- Kanker Kolorektal4 studi
- Melanoma3 studi
- Sklerosis Lateral Amiotrofik3 studi
- Kanker (semua jenis)3 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.